Our R&D approach is predicated on leveraging our unique and highly refined capability set to develop complex, difficult-to- formulate assets utilizing ANDA or 505(b)(2) pathways. We vary our approaches to best serve unmet patient needs in conjunction with a disciplined approach to risk management and IP strategy.